What research shows about CJC-1295, Ipamorelin, and Tesamorelin — mechanisms, combinations, and key distinctions.
Growth hormone secretagogues are compounds that stimulate the pituitary gland to release growth hormone rather than providing GH directly. That distinction matters. Exogenous GH bypasses the body's natural feedback systems. Secretagogues work within those systems, which is part of why this class of compounds has attracted sustained research interest.
The three compounds Lumé carries in this category, CJC-1295, Ipamorelin, and Tesamorelin, represent two distinct receptor pathways. Understanding how they differ mechanistically explains why research protocols often combine them.
Growth hormone release from the pituitary is regulated by two primary signals: growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which inhibits it. GH secretagogues work by either amplifying the GHRH signal or activating a separate receptor pathway that also triggers GH pulses.
CJC-1295 and Tesamorelin are GHRH analogues. They bind to the GHRH receptor on pituitary cells and extend or replicate the natural GHRH signal. Ipamorelin works differently: it's a ghrelin receptor agonist (also called a GHRP, growth hormone-releasing peptide). The ghrelin receptor is a separate pathway from GHRH, and activating it produces GH release through a distinct signaling cascade.
When both pathways are activated simultaneously, the result is synergistic rather than additive. Research in animal models consistently shows that combining a GHRH analogue with a ghrelin receptor agonist produces a larger, more sustained GH pulse than either compound alone at equivalent doses.
Ipamorelin is a synthetic pentapeptide and one of the most selective ghrelin receptor agonists studied. What makes it notable in the research literature is what it doesn't do as much as what it does. Earlier GHRPs like GHRP-6 and GHRP-2 were associated with significant cortisol and prolactin increases alongside GH release. Ipamorelin showed high selectivity for GH release with markedly lower cortisol and prolactin effects in animal studies.
In research models, Ipamorelin produces clean GH pulses that mimic the natural pulsatile pattern of GH secretion. The pulse amplitude is dose-dependent and the duration is relatively short (roughly 2-3 hours post-administration in most models), which preserves the pulsatile nature of GH physiology rather than creating sustained elevated levels.
CJC-1295 is a GHRH analogue with a modification that extends its half-life substantially relative to native GHRH (which is degraded in minutes). The extended half-life means CJC-1295 continues to prime the GHRH receptor for hours after administration, creating a sustained window of pituitary responsiveness to GH-releasing signals.
In research, CJC-1295 combined with Ipamorelin (the CJC/IPA stack) demonstrates the synergistic effect described above: the GHRH receptor priming from CJC-1295 amplifies the GH pulse triggered by Ipamorelin's ghrelin receptor activation. Published animal data on this combination shows GH area-under-curve values well above what either compound achieves alone.
The stack also appears to preserve IGF-1 elevation over time, which is relevant to research models studying tissue repair, lean mass maintenance, and cellular recovery processes.
Tesamorelin is also a GHRH analogue, but its research trajectory has been more focused than CJC-1295. The published literature on Tesamorelin concentrates heavily on its effects on visceral adipose tissue (VAT) and IGF-1 levels. In research models, Tesamorelin consistently reduces VAT relative to subcutaneous fat, which is a more metabolically significant distinction than total weight change.
Visceral fat is metabolically active in ways that subcutaneous fat is not: it secretes inflammatory cytokines, contributes to insulin resistance, and is associated with a different cardiovascular risk profile. Research showing selective visceral fat reduction with GHRH analogue treatment is mechanistically interesting because it points to a GH-specific pathway for VAT regulation that isn't replicated by caloric restriction alone.
The TESA/IPA stack (Tesamorelin 10mg + Ipamorelin 3mg) combines this visceral fat research angle with the synergistic GH pulse effect of adding a ghrelin receptor agonist. It's a dual-mechanism approach: Tesamorelin for sustained GHRH receptor engagement and VAT-specific IGF-1 effects, Ipamorelin for the complementary GH pulse via the ghrelin pathway.
Growth hormone secretagogue research in animal models is extensive, but a few important caveats apply to interpreting it. First, GH physiology differs meaningfully between rodents and humans, so direct extrapolation requires care. Second, most long-term secretagogue studies use controlled dosing environments that don't account for diet, sleep, and circadian rhythm variation. Third, the downstream effects of elevated IGF-1 are not uniformly positive in all research contexts and depend heavily on baseline physiology.
Researchers using these compounds in preclinical settings should account for all baseline variables and interpret results in the context of what the specific model was designed to measure.
The GHRH + GHRP combination is well-established in the preclinical literature. It's not a speculative approach. The synergy between the two receptor pathways is documented across multiple independent research groups and species.
All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. These statements and products are not intended to diagnose, treat, cure, or prevent any disease. Lumé Longevity LLC is a chemical supplier and is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Not an outsourcing facility as defined under 503B. All products are sold for research, laboratory, or analytical purposes only.